Paul Calabresi Program in Clinical-Translational Research at Mayo Clinic

梅奥诊所的 Paul Calabresi 临床转化研究项目

• 批准号: 7864327
• 负责人: LYNN C. HARTMANN
• 金额: $ 107.59万
• 依托单位: MAYO CLINIC ROCHESTER
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-09-25 至 2011-07-17
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7864327
• 关键词: Advisory Committees; Appointment; Award; Basic Science; Biology; Brain; Breast; Clinic; Clinical; Clinical Oncology; Clinical Trials; Commit; Communities; Comprehensive Cancer Center; Contracts; Development; Doctor of Philosophy; Education; Fostering; Funding; Goals; Grant; Hematology; Human; Intervention; Lymphoma; Malignant Neoplasms; Mayo Clinic Cancer Center; Medical center; Mentors; Multiple Myeloma; Oncologist; Pancreas; Performance; Phase; Physicians; Population; Productivity; Prostate; Reproduction spores; Research; Research Personnel; SECTM1 gene; Scientist; Training; Training Programs; Translational Research; Translations; Woman; Work; base; cancer care; design; experience; investigator training; medical schools; medical specialties; neuro-oncology; new technology; novel therapeutics; programs; translational study

DESCRIPTION (provided by applicant): The understanding of normal biology and the dysregulation underlying cancer has increased many fold in the past few decades, providing the biomedical community with unprecedented amounts of new information and new technology to apply to human cancer. The translation of these basic science discoveries into better cancer care is a national priority. To achieve this goal, we need well-trained clinician investigators and PhD- prepared translational researchers who are focusing on the clinical-translational interface. Mayo Clinic has an outstanding reputation in clinical and translational research, including the performance of high-quality, practice-changing clinical trials. Mayo Clinic Cancer Center (MCCC), an NCI designated comprehensive cancer center, is in its 31st year of continuous NCI funding. Its clinical-translational portfolio is particularly strong with a Phase I grant and Phase II contract from NCI, and SPORE funding in prostate, pancreas, brain, lymphoma, myeloma, and pending in breast. In addition, Mayo is a highly regarded center for medical training. The Mayo Graduate School of Medicine is one of the largest training programs in the world, training 1400 physicians yearly in over 100 specialties. Thus, the MCCC is well poised to provide an outstanding training experience for academic oncologists. The NCI's "Paul Calabresi Award for Clinical Oncology (K12) Training Program" is designed to foster the development of physician scientists conducting hypothesis-based, clinical-translational studies in cancer. MCCC has been fortunate to hold such an award since 2001, providing training for eight Paul Calabresi Scholars to date. These promising junior investigators all currently hold academic appointments and have shown excellent academic productivity. We seek to continue our Paul Calabresi Program and to expand it to include PhD-prepared scientists committed to clinical-translational research. Paul Calabresi Scholars may choose from among six research tracks within MCCC: Gl malignancies, GU malignancies, hematology, neuro-oncology, novel therapeutics and women's cancers. Our mentors are highly experienced and well-funded. The program is led by Lynn C. Hartmann, MD, Associate Director for Education of MCCC, and an Advisory Committee made up of senior MCCC leaders. With this program we will train investigators to conduct hypothesis-based research in team research settings where basic, population and clinical scientists work together to expedite the translation of basic research discoveries into clinically beneficial interventions in cancer.

描述（由申请人提供）：在过去的几十年里，对正常生物学和癌症基础失调的理解增加了许多倍，为生物医学界提供了前所未有的大量新信息和新技术来应用于人类癌症。将这些基础科学发现转化为更好的癌症护理是国家的首要任务。为了实现这一目标，我们需要训练有素的临床研究人员和专注于临床转化界面的博士转化研究人员。梅奥诊所在临床和转化研究领域享有盛誉，包括开展高质量、改变实践的临床试验。 Mayo Clinic 癌症中心 (MCCC) 是 NCI 指定的综合癌症中心，今年已是 NCI 持续资助的第 31 个年头。其临床转化组合尤其强大，拥有 NCI 的 I 期拨款和 II 期合同，以及前列腺、胰腺、脑、淋巴瘤、骨髓瘤和待定的乳腺癌领域的 SPORE 资金。此外，梅奥还是备受推崇的医疗培训中心。梅奥医学研究生院是世界上最大的培训项目之一，每年培训 100 多个专业的 1400 名医生。因此，MCCC 已做好准备为学术肿瘤学家提供出色的培训经验。 NCI 的“Paul Calabresi 临床肿瘤学奖 (K12) 培训计划”旨在促进从事基于假设的癌症临床转化研究的医师科学家的发展。 MCCC 自 2001 年以来一直有幸获得这样的奖项，迄今为止已为八位 Paul Calabresi 学者提供了培训。这些有前途的初级研究人员目前都担任学术职务，并表现出了出色的学术生产力。 我们寻求继续开展保罗·卡拉布雷西计划，并将其扩展至包括致力于临床转化研究的博士科学家。 Paul Calabresi 学者可以从 MCCC 内的六个研究方向中进行选择：胃肠道恶性肿瘤、胃肠道恶性肿瘤、血液学、神经肿瘤学、新型疗法和女性癌症。我们的导师经验丰富且资金雄厚。该计划由 MCCC 教育副总监 Lynn C. Hartmann（医学博士）和由 MCCC 高级领导组成的咨询委员会领导。通过该计划，我们将培训研究人员在团队研究环境中进行基于假设的研究，基础科学家、人口科学家和临床科学家共同努力，加快将基础研究发现转化为临床有益的癌症干预措施。